For high-profile biotech Viking Therapeutics(NASDAQ: VKTX), Monday was very much a good news/bad news kind of day. The company reported quite encouraging clinical results from a version of its investigational weight-loss drug. Before long, however, this was overshadowed by promising news from rival developers of similar treatments.
Ultimately, after an early surge, Viking's shares closed the day more than 13% lower in price.
Weight loss for profit gain
Viking presented those results at ObesityWeek, the annual meeting of scientific interest group the Obesity Society. Its presentations of that weight loss drug, VK2735, revealed that patients administered the highest dose of the drug in pill form lost over 8% of their body weight over a four-week period. This compared very favorably to the 1.4% recorded by patients taking a placebo, and also topped analyst expectations of 5% to 6%.
Investors had been particularly interested in the VK2735 pill because the leading Food and Drug Administration (FDA) GLP-1 drugs approved for obesity are administered via injection. Specifically, these are Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
Yet Viking's happy news was quickly overshadowed at the event by progress reported by other weight-loss drug developers.
In its own presentation at the event, global pharmaceutical companyAstraZeneca revealed that patients with type 2 diabetes who took the company's investigational drug saw a nearly 6% weight reduction. Meanwhile, Corbus Pharmaceuticals said that mice administered the highest dose of its pipeline drug experienced a weight reduction of over 31%.
Still on the right track
With these presentations, it's abundantly clear the obesity drug gold rush is only intensifying. The sky-high demand for weight loss drugs -- particularly in obesity-heavy America -- combined with the few advanced products currently available, make for quite the opportunity. Investors shouldn't get discouraged about this mounting competition for Viking, as the biotech clearly has an efficacious drug and is well advanced in developing it for commercialization.
Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
- Amazon: if you invested $1,000 when we doubled down in 2010, you’d have $22,292!*
- Apple: if you invested $1,000 when we doubled down in 2008, you’d have $42,169!*
- Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $407,758!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
*Stock Advisor returns as of November 4, 2024
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends AstraZeneca Plc and Novo Nordisk. The Motley Fool has a disclosure policy.
